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Abstract
Background: Within the Brazilian Unified Health System (SUS), Referral Centers (RCs) are care facilities that provide
specialized services. The objective of this study was to evaluate the efficacy of care provided to patients with
multiple myeloma (MM) at a specialized RC (Hospital de Clínicas de Porto Alegre Referral Center for Multiple
Myeloma, CRMM-HCPA) and to compare quality of life between patients with MM treated at CRMM-HCPA and
those treated at non-RC facilities.
Methods: A 6-month cohort study was conducted in patients with MM receiving thalidomide from the Rio Grande
do Sul State Health Department and treated at CRMM-HCPA and patients receiving treatment at other, non-RC care
facilities. Thirty-two patients were included in the study, 19 from CRMM-HCPA and 13 from other institutions. To
analyze the efficacy of care provided at CRMM-HCPA, the main outcome measure was the time from diagnosis to
referral for autologous hematopoietic stem cell transplantation (HSCT). This outcome measure was assessed using
questionnaires specifically designed for this study. Quality of life was also assessed, using the SF-36 questionnaire.
Results: Time from MM diagnosis to referral for autologous HSCT in each group was measured only in patients
aged ≤ 65 years (n = 25); of these, 15 were recruited from CRMM-HCPA and 10 from other institutions. In this
analysis, there was a significant difference (p = 0.036) in time elapsed between diagnosis and referral for autologous
HSCT, which was significantly shorter for patients treated at CRMM-HCPA (median, 9 months; IQR, 8.5–14.5) than for
those treated elsewhere (median, 24 months; IQR, 16–24). On quality of life analysis, there was a significant
difference in the Social Functioning domain of the SF-36 questionnaire, which relates to performance of social
activities (p = 0.02).
Conclusions: The Referral Center model provided seems to be a more efficient treatment strategy as compared with
other health care facilities, as it enabled a reduction in time to transplantation. Patients treated at CRMM-HCPA
demonstrated greater ease in performing social activities, with less interference from physical or emotional problems.
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Background
Within the Brazilian Unified Health System (Sistema
Único de Saúde, SUS), Referral Centers (RCs) are spe-
cialized facilities that provide care as part of an innova-
tive partnership between academia and SUS managers.
The main objectives of a RC are to provide multidiscip-
linary care and follow-up, facilitate access to specialized
medicines provided by the State Health Departments
(SHDs), and enable creation of care quality indicators to
improve public health management.
In many conditions, to ensure recovery, enable proper
dose adjustment of pharmaceutical therapy, reduce waste-
fulness, and prevent further suffering to patients, it is
essential that the management strategy involve continuous
care, guaranteed access to medicines, and close monitor-
ing of the positive and negative effects of treatment [1].
RCs should implement all guidance advocated in the
Clinical Protocols and Practice Guidelines published by
the Brazilian Ministry of Health (MoH) [1, 2]. With their
experience in providing short- and long-term specialty
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care and follow-up, RCs have become an environment
conducive to academic and research activities to better
serve the SUS. Furthermore, they have enabled the per-
formance of clinical efficacy research and clinical trials in
areas relevant to the SUS.
Through the RC framework, the SHDs – which dis-
pense to the population all medicines provided by the
MoH Specialized Component of Pharmaceutical Assist-
ance (Programa do Componente Especializado) – can
achieve greater control of the volume of medicines
required.
At Hospital de Clínicas de Porto Alegre (HCPA), a ter-
tiary referral center and major teaching hospital in Porto
Alegre, state of Rio Grande do Sul, Brazil, the operation
of a RC is based on the provision of care, in accordance
with the treatment routine necessary for treatment of the
condition, by a multidisciplinary team of professionals
from both the HCPA and the SHD, as well as by under-
graduate and graduate students from institutions of higher
learning. The expected result of this cooperation is im-
proved access to medicines, treatment adherence, and
user satisfaction, as well as savings brought on by im-
proved pharmaceutical management, benefiting patients
and the two public institutions alike.
RCs also enable the compilation of specific databases
and registries, which can be used in the conduction of
clinical efficacy research and for information management
purposes, further strengthening technical cooperation
among public health institutions and making RCs a very
important tool in supporting decision-making and public
policymaking by the MoH and, more directly, by SHDs.
Multiple myeloma (MM) is a B-cell neoplasm that
affects immunoglobulin (antibody)-producing plasma
cells. It is characterized by plasma-cell infiltration of
the bone marrow, anchored by endothelial growth fac-
tors, and is associated with the action of adhesion mol-
ecules, interleukin (IL)-6, IL-3, IL-1 beta, and IL-10,
granulocyte- and monocyte-stimulating factors, and
tumor necrosis factor alpha.
MM is incurable [3, 4], and may be treated with
chemotherapy and new treatment modalities such as
proteasome inhibitors and/or immunomodulators, in-
cluding thalidomide. In the late 1990s, the first reports
of thalidomide in the treatment of MM changed the en-
tire panorama of the disease, and VAD (vincristine,
doxorubicin [Adriamycin], and dexamethasone) chemo-
therapy fell into disuse [5].
The choice of anti-myeloma therapy scheme depends
on factors such as age, performance status, and presence
of comorbidities. Patients younger than 65 years, with
performance status 0, 1, or 2, and no severe comorbidi-
ties (other neoplasm, grade III–IV heart failure, AIDS
with CD4 counts < 200) are candidates for autologous
hematopoietic stem cell transplantation (autologous
HSCT) immediately after induction therapy [6–9]. Au-
tologous HSCT is the gold-standard treatment for pa-
tients under the age of 70, and is known to produce
complete remission lasting many years [8, 10, 11]. Delays
in treatment initiation have a negative impact on patient
response and can delay escalation of therapy to other
stages, such as HSCT.
The HCPA Multiple Myeloma Referral Center (Centro
de Referência de Mieloma Múltiplo, CRMM-HCPA) was
established in 2010 to eliminate obstacles to access to
SHD-dispensed thalidomide and reduce delays between
diagnosis and start of treatment for patients with MM.
All MM patients treated via the SUS receive thalidomide
in accordance with the National Guidelines for MM, but
time to treatment access varies between the different in-
stitutions that provide services to SUS.
Taking into account that the services provided by a RC
may be considered a new health technology, the present
study sought to assess the efficacy of these services
within the SUS framework. The main outcome measure
was time elapsed between diagnosis of MM and referral
for autologous HSCT.
Methods
We conducted an efficacy analysis of the care provided
at CRMM nested in a 6-month ambispective cohort of
patients with MM who were receiving thalidomide treat-
ment at CRMM-HCPA, from May 2012 to May 2014.
All study procedures were approved by the Research
Ethics Committee at Hospital de Clínicas de Porto Ale-
gre (no. 283.728). The comparator group was a sample
of patients with MM who were being treated at other fa-
cilities. The main outcome measure was the time be-
tween diagnosis of MM and referral for HSCT. We also
compared quality of life parameters and health service
costs between the two groups.
Sample
The study sample comprised 32 participants with MM
who were on thalidomide therapy, all of whom were
referred for transplantation: 19 treated at CRMM-
HCPA and 13 treated at other health care facilities in
the state (control group). All were registered with the
SHD and provided written informed consent for
participation.
Procedures
Patients from CRMM-HCPA were identified through the
records of the hospital’s outpatient MM clinic, where
they receive routine care through the SUS. Patients from
other institutions were identified from the RS SHD
Registry, which was accessed through the Department’s
own electronic system. This Registry contains personal
information for the patients, such as addresses and
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telephone numbers, and is used to control dispensation
of medicines supplied by the SHD. All participants of
this study were treated through the SUS. In the city of
Porto Alegre, these patients are referred for treatment at
public hospitals after attending municipal-run health
clinics; the destination hospital depends on the patient’s
home address (Fig. 1).
The quality of life instrument (SF-36 v.2) and a health
resources utilization questionnaire were administered to
all participants at inclusion (I1) and at the 6-month
study visit (I2). At I1, participants also completed a
questionnaire designed to collect demographic and treat-
ment data. The SF-36 v.2 was completed without investi-
gator interference. Scores were calculated for analysis of
physical, mental, and social functioning.
The health resources utilization questionnaire was
employed for comparative analysis of the costs to the
SUS of patients treated at the CRMM versus those of
patients treated in other facilities.
All hospital cost analyses were conducted from a SUS
perspective and all costs were drawn from the SUS mas-
ter table, as reported by the HCPA billing sector.
Statistical analysis
For SF-36 v.2 calculation, items were transformed into
domains. A different calculation formula is used for each
domain. Scores range from 0 to 100, and were calculated
with the Health Outcomes Scoring Software 4.5.
In quality of life assessment, descriptive statistical
methods were used to obtain measures such as means,
standard deviations, and standard errors.
All statistical analyses were carried out in PASW Sta-
tistics 18 for Windows. The significance level was set at
p < 0.05.
The remaining variables of interest were: sex (male or
female); age at diagnosis; educational attainment; and
quality of life. Fisher’s exact test was used for analysis of
sex and educational attainment data, whereas Student’s
t-test was used for analysis of age at diagnosis (mean ±
standard deviation). The Mann–Whitney U test was
used for the variable duration of treatment (median
and IQR) in months, and for analysis of time elapsed
between diagnosis and referral for HSCT.
For within-group analysis of P-values for cost and
quality of life data, we conducted a comparative analysis
by means of the generalized linear models method with
Bonferroni multiple comparisons.
Results
Quality of life analysis (Table 1) revealed a significant
between-group difference in the Social Role Functioning
domain, which pertains to involvement in social activities
(p = 0.02), in favor of the CRMM group.
Table 2 describes the profile of the participants, includ-
ing variables such as sex, age, site of thalidomide collec-
tion, treatment duration, and educational attainment. Of
Fig. 1 Time from diagnosis to referral for transplantation
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the 32 participants in the sample, 19 were female and 13
were male. Mean age was 55 years in the CRMM group
and 61 years in the other facilities group (Other), with no
significant difference.
Figure 1 shows the difference in time from diagnosis
to referral for transplantation between the two study
groups (CRMM vs. other facilities). In each group, time
from diagnosis to referral for HSCT was measured only
in participants aged ≤ 65 years (n = 25), of whom 15 were
in the CRMM group and 10 were in the other facilities
group. Overall, nine patients (60 %) in the CRMM group
underwent transplantation, versus five (50 %) in the
other facilities group.
In this analysis, we found a significant difference
(p = 0.036) in time elapsed between diagnosis and referral
for HSCT, with patients treated at CRMM being referred
for transplantation significantly sooner (median, 9 months;
IQR, 8.5–14.5) than patients treated elsewhere (median,
24 months; IQR, 16–24).
Between-group comparison of time from diagnosis to
first thalidomide dispensation (Fig. 2) again showed a
significant difference (p < 0.001, Mann–Whitney U), with
a median time to thalidomide collection of 0.5 months
(IQR, 0.5–3 months) in the CRMM group versus
3 months (IQR, 3–4 months) in the other facilities
group.
Table 1 Comparative analysis of quality of life
Quality of life variables Interview 1 Interview 2 p* Mean difference Final mean difference p**
Mean (SEM) Mean (SEM) (95 % CI) (95 % CI)
Physical Functioning
CRMM 28.8 (2.3) 28.2 (2.5) 0.748 −0.49 (−2.73;1.74) −2.78 (−6.41;0.84) 0.13
Other 34.1 (3.0) 35.4 (3.1) 0.338 2.29 (−0.44;5.01)
Physical Role Functioning
CRMM 30.9 (1.6) 33.6 (1.5) 0.043 1.93 (−0.33;4.19) 2.89 (−0.77;6.56) 0.12
Other 36.6 (3.1) 35.9 (3.7) 0.694 −0.97 (−3.72;1.79)
Bodily Pain
CRMM 41.2 (3.2) 43.1 (3.1) 0.304 3.65 (1.47;5.83) 1.49 (−1.96;4.94) 0.40
Other 38.3 (2.7) 40.5 (2.8) 0.035 2.16 (−0.47;4.80)
General Health Perceptions
CRMM 53.7 (1.8) 50.6 (2.0) 0.158 −2.02 (−5.63;1.58) 1.91 (−4.27;8.08) 0.55
Other 43.5 (2.7) 42.8 (2.8) 0.717 −3.93 (−8.41;0.55)
Vitality
CRMM 47.1 (2.2) 47.8 (2.5) 0.734 1.32 (−1.68;4.31) −2.98 (−7.72;1.76) 0.22
Other 44.1 (3.1) 49.9 (2.4) 0.004 4.30 (0.67;7.92)
Social Role Functioning
CRMM 45.7 (2.9) 49.2 (2.8) 0.094 4.96 (2.02;7.90) 5.81 (1.04;10.57) 0.02
Other 38.1 (2.9) 39.6 (3.0) 0.345 −0.84 (−4.43;2.74)
Emotional Role Functioning
CRMM 29.6 (1.5) 33.1 (1.3) 0.042 3.39 (0.80;5.99) 2.00 (−2.13;6.13) 0.34
Other 31.8 (3.0) 33.4 (3.4) 0.127 1.40 (−1.75;4.54)
Mental Health
CRMM 42.7 (3.3) 43.8 (3.4) 0.634 0.82 (−3.27;4.90) −3.70 (−10.22;2.81) 0.27
Other 39.0 (3.3) 45.4 (3.1) 0.038 4.52 (−0.44;9.47)
Physical Component Summary
CRMM 37.9 (1.9) 37.5 (1.9) 0.729 0.03 (−1.53;1.60) 0.46 (−2.03;2.95) 0.72
Other 39.1 (2.4) 38.4 (2.5) 0.483 −0.43 (−2.32;1.47)
Mental Component Summary
CRMM 43.8 (2.6) 46.6 (2.7) 0.169 3.17 (0.12;6.22) 0.29 (−4.63;5.21) 0.91
Other 38.7 (2.6) 43.8 (2.4) 0.006 2.88 (−0.83;6.60)
*Generalized Estimating Equations, Bonferroni’s corrected multiple comparisons
**Analysis of covariance, adjusted for baseline values
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Table 2 Demographic and treatment characteristics of the sample
Variable CRMM Other p
(n = 19) n (%) (n = 13) n (%)
Sex 0.471*
Female 10 (52.6 %) 9 (69.2 %)
Male 9 (47.4 %) 4 (30.8 %)
Age at diagnosis, mean (standard deviation) 55.3 (11.1) 61.3 (11.2) 0.145**
Place of residence 0.720*
Porto Alegre 7 (36.8 %) 6 (46.2 %)
Other municipalities in Rio Grande do Sul 12 (63.2 %) 7 (53.8 %)
Thalidomide collection site
HCPA 19 (100 %)
Municipal pharmacy 9 (69.2 %)
SHD pharmacy 4 (30.8 %)
Treatment duration in months, median (IQR) 20 (12–36) 24 (12–36) 0.248***
Educational attainment 0.351*
Primary education 9 (52.9 %) 3 (25.0 %)
Secondary education 5 (29.4 %) 6 (50.0 %)
Higher education 3 (17.6 %) 3 (25.0 %)




Fig. 2 Time from diagnosis to thalidomide collection
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No significant between-group differences were found
in the questionnaire items regarding treatment costs
(Table 3).
Discussion
Taking into account that autologous HSCT is the gold-
standard treatment for MM [10, 11], any intervention that
may influence this indicator or even improve the quality
of life of these patients can be immensely valuable.
We found significant between-group differences in time
to referral for HSCT, quality of life (specifically in the so-
cial aspect), and time between diagnosis and initiation of
thalidomide therapy.
Tricot et al. found that ≤ 12 months of pharmacotherapy
preceding transplantation increased event-free survival in
patients with MM [12].
Therefore, the 75-day difference in referral for HSCT
between patients treated at CRMM-HCPA and patients
treated at other facilities may have been associated with
the improved quality of life found in patients in the
former group. A larger study is required to assess poten-
tial differences in survival.
Study limitations
We initially expected to include a much greater number
of participants; however, patient inclusion was fraught
with difficulty, particularly because many had transpor-
tation issues that prevented them from attending ques-
tionnaire administration visits at the study site and
because of incorrect data in the SHD registry, which
precluded contact with many potential participants. In
addition, the small sample size and limited evaluation
time did not allow us to draw any conclusions as to the
potential impact on patient survival.
Furthermore, the fact that questionnaire items asked
participants to recall events occurring in the “last
6 months” may have been a hindrance, as we believe
reliable recall this far back may be quite difficult for
certain items. Nevertheless, we did not conduct a for-
mal assessment of whether this factor could introduce
bias or interfere with results, as a similar 6-month
period is used in other, validated questionnaires, such
as the SF-36 v2.
We found that few studies have assessed the efficacy
or cost-effectiveness of SUS services in Brazil, which
limited the methodological framework available to us.
HCPA is the only facility in the state of Rio Grande do
Sul that provides a RC for MM. The presence of other
such centers in the state, at other facilities where pa-
tients collect SHD-provided medicines, would have en-
abled a multicenter analysis and increased the sample of
participants, which would have improved the quality of
the results obtained.
The findings of this study may be useful to other
Brazilian states and even to other countries.
Conclusions
The RC treatment strategy seems to be more efficient
than the comparator group, as it facilitated access to
medicines and enabled a significant reduction in time
elapsed between diagnosis of MM and referral for
HSCT.
Table 3 Comparison of treatment costs (US$)
Interview 1 Interview 2
Cost variable Mean (SEM) Mean (SEM) p* Mean difference (95 % CI) Final mean difference (95 % CI) p**
Blood tests
CRMM 161.5 (11.8) 121.6 (16.1) 0.009 −38.51 (−64.66;-12.37) −13.29 (−55.79;29.20) 0.54
Other 159.1 (17.0) 140.8 (19.7) 0.242 −25.22 (−58.26;7.82)
X-rays, bone
CRMM 27.9 (6.5) 15.6 (5.6) 0.011 −10.93 (−17.93;-3.94) −4.87 (−16.27;6.52) 0.40
Other 19.2 (5.7) 16.9 (5.3) 0.552 −6.06 (−14.91;2.7)
X-rays, chest
CRMM 11.0 (3.3) 5.5 (1.9) 0.047 −6.57 (−10.40;-2.74) −3.52 (−9.81;2.77) 0.27
Other 18.3 (3.9) 12.7 (4.1) 0.068 −3.05 (−7.91;1.81)
Urine tests
CRMM 92.2 (7.0) 73.6 (9.7) 0.018 −16.81 (−30.15;-3.47) −8.66 (−31.17;13.86) 0.45
Other 59.4 (13.2) 55.6 (14.6) 0.512 −8.15 (−25.25;8.95)
Total
CRMM 292.6 (23.3) 216.2 (30.1) 0.003 −70.41 (−115.40;-25.41) −24.09 (−97.32;49.15) 0.52
Other 256.0 (25.4) 226.0 (30.6) 0.268 −46.32 (−103.20;10.56)
*Generalized Estimating Equations, Bonferroni’s corrected multiple comparisons
**Analysis of covariance, adjusted for baseline
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Furthermore, patients treated in the RC setting demon-
strated greater ease in performing social activities – such
as visiting family, friends, and neighbors – with less inter-
ference from physical and emotional problems as com-
pared with patients treated at the other facilities.
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